Zealand Pharma AS (ZLDPF)
(Delayed Data from OTC)
$72.07 USD
-1.24 (-1.69%)
Updated Sep 19, 2025 11:21 AM ET
3-Hold of 5 3
B Value A Growth D Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ZLDPF 72.07 -1.24(-1.69%)
Will ZLDPF be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ZLDPF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ZLDPF
Eli Lilly (LLY) Q1 Earnings Lag Estimates
Zealand Pharma AS (ZLDPF) Stock Jumps 8.0%: Will It Continue to Soar?
ZLDPF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q1 Earnings and Revenue Estimates
Repligen (RGEN) Moves 3.7% Higher: Will This Strength Last?
Zealand Pharma A/S (ZLDPF) Reports Q3 Loss, Lags Revenue Estimates
Other News for ZLDPF
M&A News: 89bio Stock (ETNB) Jumps 83% on $3.5B Acquisition by Roche
J.P. Morgan Reaffirms Their Buy Rating on Zealand Pharma (ZLDPF)
SA Asks: Which biotechs could be acquired by year's end?
Metsera: An Emerging Contender In The GLP???1 Arena
Zealand Pharma A/S (ZLDPF) Presents at Cantor Global Healthcare Conference 2025 Transcript